The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for
short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary
tract infection in females.
Phase:
Phase 4
Details
Lead Sponsor:
Dr Cipto Mangunkusumo General Hospital
Collaborators:
Astellas Pharma Indonesia Inc. Pharos Life Corporation